These experiments are also important because they suggest that manipulation of the intracellular reducing environment, by glucose or by the glutathione reductase inhibitor BCNU (which decreases peroxide detoxification by the GSH-GSH peroxidase cycle), may affect the redox metabolism of doxorubicin in whole tumor cells. Here, GSR is linked to neoplasm.